BELLICUM PHARMACEUTICALS (BLCM) saw its loss widen to $17.72 million, or $0.66 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $13.41 million, or $0.51 a share.
Revenue during the quarter surged 100 percent to $0.11 million from $0.06 million in the previous year period.
Operating loss for the quarter was $17.43 million, compared with an operating loss of $13.62 million in the previous year period.
"We are pleased with recent progress, as the pediatric trial of our lead product candidate BPX-501 continues to enroll at a strong pace. We are preparing for a comprehensive data update of this program at ASH 2016, and are working with regulators in the European Union and the U.S. to finalize registration pathways for BPX-501 and rimiducid," said Tom Farrell, president and chief executive officer of Bellicum. "In the coming weeks, we expect to initiate the Phase 1 clinical trials of our BPX-601 GoCAR-T and BPX-701 TCR product candidates. We continue to build upon our differentiated technology platform and believe its potential to address the safety and efficacy issues of adoptive cell therapies will provide competitive advantage."
Working capital declinesBELLICUM PHARMACEUTICALS has witnessed a decline in the working capital over the last year. It stood at $98.91 million as at Sep. 30, 2016, down 10.33 percent or $11.39 million from $110.30 million on Sep. 30, 2015. Current ratio was at 12.40 as on Sep. 30, 2016, down from 22.98 on Sep. 30, 2015. Days sales outstanding went down to 186 days for the quarter compared with 686 days for the same period last year.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
